BioCryst Pharmaceuticals, Inc. Fundamental Analysis (NASDAQ: BCRX)
BioCryst Pharmaceuticals, Inc. Fundamental Analysis (NASDAQ: BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shows weak financial fundamentals with a PE ratio of -5.64, profit margin of -51.71%, and ROE of 1.24%. The company generates $0.9B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 35.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BCRX's fundamental strength across five key dimensions:
Efficiency Score
WeakBCRX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentBCRX trades at attractive valuation levels.
Growth Score
ModerateBCRX shows steady but slowing expansion.
Financial Health Score
ExcellentBCRX maintains a strong and stable balance sheet.
Profitability Score
ModerateBCRX maintains healthy but balanced margins.
Key Financial Metrics
Is BCRX Expensive or Cheap?
P/E Ratio
BCRX trades at -5.64 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, BCRX's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values BioCryst Pharmaceuticals, Inc. at -4.26 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -4.80 times EBITDA. This is generally considered low.
How Well Does BCRX Make Money?
Net Profit Margin
For every $100 in sales, BioCryst Pharmaceuticals, Inc. keeps $-51.71 as profit after all expenses.
Operating Margin
Core operations generate -43.11 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.24 in profit for every $100 of shareholder equity.
ROA
BioCryst Pharmaceuticals, Inc. generates $-98.48 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BioCryst Pharmaceuticals, Inc. generates strong operating cash flow of $311.41M, reflecting robust business health.
Free Cash Flow
BioCryst Pharmaceuticals, Inc. generates strong free cash flow of $308.55M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.21 in free cash annually.
FCF Yield
BCRX converts 11.87% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-5.64
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.001
vs 25 benchmark
P/B Ratio
Price to book value ratio
-4.26
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.80
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-1.55
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.91
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
1.24
vs 25 benchmark
ROA
Return on assets percentage
-0.98
vs 25 benchmark
ROCE
Return on capital employed
-1.42
vs 25 benchmark
How BCRX Stacks Against Its Sector Peers
| Metric | BCRX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -5.64 | 29.15 | Better (Cheaper) |
| ROE | 123.57% | 492.00% | Weak |
| Net Margin | -51.71% | -11576.00% (disorted) | Weak |
| Debt/Equity | -1.55 | 0.79 | Strong (Low Leverage) |
| Current Ratio | 1.91 | 5.18 | Neutral |
| ROA | -98.48% | -131.00% (disorted) | Weak |
BCRX outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BioCryst Pharmaceuticals, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation